Apogee Therapeutics Inc

NASDAQ:APGEUnited States

Today

Show headlines and story abstract

• Apogee Therapeutics' Q1 Net Loss Widens, from 6 hours ago by MT Newswires

  6 hours ago by MT Newswires
  Companies Mentioned: APGE
  07:42 AM EDT, 05/13/2024 (MT Newswires) -- Apogee Therapeutics (APGE) reported a Q1 net loss Monday of $32.1 million, widening from its $12.5 million net loss a year earlier. Analysts polled by Capital IQ expected a net loss of $28.9 million. The c...

• Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results, from 7 hours ago by GlobeNewswire

  7 hours ago by GlobeNewswire
  Companies Mentioned: APGE

• Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results, from 7 hours ago by Dow Jones

  7 hours ago by Dow Jones
  Companies Mentioned: APGE
  
  "potential," "develop," "plan" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Apogee believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Apogee's filings with the U.S. Securities and Exchange Commission (the SEC)), many of which are beyond the company's control and subject to change. Actual results could be materially different. Risks and uncertainties include: global macroeconomic conditions and related volatility, expectations regarding the initiation, progress, and expected results of Apogee's preclinical studies, clinical trials and research and development programs; expectations regarding the timing, completion and outcome of Apogee's clinical trials; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in Apogee's Annual Report on 10-K for the year period ended December 31, 2023, filed with the SEC on March 5, 2024, and subsequent disclosure documents we may file with the SEC. Apogee claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Apogee expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.
  

• Press Release: Apogee Therapeutics Highlights Pipeline Progress and Reports First Quarter 2024 Financial Results, from 7 hours ago by Dow Jones

  7 hours ago by Dow Jones
  Companies Mentioned: APGE
  
  "potential," "develop," "plan" or the negative of these terms, and similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. While Apogee believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to the company on the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties (including, without limitation, those set forth in Apogee's filings with the U.S. Securities and Exchange Commission (the SEC)), many of which are beyond the company's control and subject to change. Actual results could be materially different. Risks and uncertainties include: global macroeconomic conditions and related volatility, expectations regarding the initiation, progress, and expected results of Apogee's preclinical studies, clinical trials and research and development programs; expectations regarding the timing, completion and outcome of Apogee's clinical trials; the unpredictable relationship between preclinical study results and clinical study results; the timing or likelihood of regulatory filings and approvals; liquidity and capital resources; and other risks and uncertainties identified in Apogee's Annual Report on 10-K for the year period ended December 31, 2023, filed with the SEC on March 5, 2024, and subsequent disclosure documents we may file with the SEC. Apogee claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. Apogee expressly disclaims any obligation to update or alter any statements whether as a result of new information, future events or otherwise, except as required by law.